| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Dr. Stone is Clinical Director, Adult Acute Leukemia Program, Dana-Farber Cancer Institute and Associate Professor of Medicine, Harvard Medical School, Boston, MA.
Acute myeloid leukemia (AML) in older adults is a biologically and clinically distinct entity. Based on analysis of cytogenetic and molecular data, it is known that leukemic cells in older patients are intrinsically resistant to standard chemotherapy. Due to comorbid disease and impaired bone marrow stem cell reserve, older adults tolerate myelosuppressive chemotherapy poorly, with a treatment-related mortality rate of 25 percent. About 35 percent of adults under age 40 are cured, but the complete remission rate (likelihood of temporary disease eradication) is 45 percent in those over age 60, considerably lower than the 75% rate among younger patients, and the possibility of long-term disease free survival is 20 percent in those achieving remission or less than 10 percent overall. Standard allogeneic bone marrow transplantation is too dangerous to be considered as a means to eradicate minimal residual disease after remission is obtained and myelointensive chemotherapy is not a beneficial post-remission strategy in this age cohort. These disappointing results call for more effective and less toxic therapeutic options. Advances in our understanding of the pathophysiology of AML and promising early clinical data suggest that the era of truly targeted therapy in this difficult disease may soon be a reality.
This article has been cited by other articles:
|
|
 |
|
  J.-L. Harousseau, G. Martinelli, W. W. Jedrzejczak, J. M. Brandwein, D. Bordessoule, T. Masszi, G. J. Ossenkoppele, J. A. Alexeeva, G. Beutel, J. Maertens, et al. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older Blood, August 6, 2009; 114(6): 1166 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Fehniger, J. C. Byrd, G. Marcucci, C. N. Abboud, C. Kefauver, J. E. Payton, R. Vij, and W. Blum Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13 Blood, January 29, 2009; 113(5): 1002 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F Cashen, G. J. Schiller, M. R. O'Donnell, J. S. Larsen, A. Baranwal, M. T Cullen, and J. F DiPersio Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML) Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 560 - 560. [Abstract]
|
|
|
|
 |
|
 M. Yanada, G. Garcia-Manero, G. Borthakur, F. Ravandi, H. Kantarjian, and E. Estey Relapse and death during first remission in acute myeloid leukemia Haematologica, April 1, 2008; 93(4): 633 - 634. [Full Text] [PDF]
|
|
|
|
 |
|
 A Gondos, B Holleczek, V Arndt, C Stegmaier, H Ziegler, and H Brenner Trends in population-based cancer survival in Germany: to what extent does progress reach older patients? Ann. Onc., July 1, 2007; 18(7): 1253 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Anensen, A. M. Oyan, J.-C. Bourdon, K. H. Kalland, O. Bruserud, and B. T. Gjertsen A Distinct p53 Protein Isoform Signature Reflects the Onset of Induction Chemotherapy for Acute Myeloid Leukemia. Clin. Cancer Res., July 1, 2006; 12(13): 3985 - 3992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Sekeres Non-Transplant Therapy for Older Adults with Acute Myeloid Leukemia J Natl Compr Canc Netw, January 1, 2006; 4(1): 51 - 56. [Abstract] [PDF]
|
|
|
|
|
|
P. A. Mehta, T. A. Alonzo, R. B. Gerbing, J. S. Elliott, T. A. Wilke, R. J. Kennedy, J. A. Ross, J. P. Perentesis, B. J. Lange, and S. M. Davies XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report Blood, January 1, 2006; 107(1): 39 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Kaufmann, J. E. Karp, L. Letendre, T. J. Kottke, S. Safgren, J. Greer, I. Gojo, P. Atherton, P. A. Svingen, D. A. Loegering, et al. Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia Clin. Cancer Res., September 15, 2005; 11(18): 6641 - 6649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Marcucci, W. Stock, G. Dai, R. B. Klisovic, S. Liu, M. I. Klisovic, W. Blum, C. Kefauver, D. A. Sher, M. Green, et al. Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity J. Clin. Oncol., May 20, 2005; 23(15): 3404 - 3411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia Blood, February 1, 2005; 105(3): 959 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Stone, D. J. DeAngelo, V. Klimek, I. Galinsky, E. Estey, S. D. Nimer, W. Grandin, D. Lebwohl, Y. Wang, P. Cohen, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Blood, January 1, 2005; 105(1): 54 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. H. Yee, M. Schittenhelm, A.-M. O'Farrell, A. R. Town, L. McGreevey, T. Bainbridge, J. M. Cherrington, and M. C. Heinrich Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells Blood, December 15, 2004; 104(13): 4202 - 4209. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |
